Heparin-induced thrombocytopenia: Real-world issues

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 6, 2011, Pages 653-663

  Linkins, Lori Ann ^a   Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

danaparoid; direct thrombin inhibitors; fondaparinux; Heparin induced thrombocytopenia; prothrombotic

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; DIRECT THROMBIN INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; DISEASE COURSE; DISEASE SEVERITY; DRUG HALF LIFE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ORTHOPEDICS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORTHOPEDIC PROCEDURES; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS; WOUNDS AND INJURIES;

EID: 79960629597     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1291375     Document Type: Article

References (46)

1. Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992 68 1 95-96
2. Warkentin T E. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010 24 4 755-775 ix
3. Warkentin T E., Chong B H., Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998 79 1 1-7 (Pubitemid 28037046)
4. Sheridan D, Carter C, Kelton J G. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986 67 1 27-30 (Pubitemid 16167006)
5. Warkentin T E., Kelton J G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996 101 5 502-507 (Pubitemid 126335970)
6. Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003 110 2-3 73-82 (Pubitemid 37329444)
7. Warkentin T E., Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001 135 7 502-506 (Pubitemid 32923567)
8. Socher I, Kroll H, Jorks S, Santoso S, Sachs U J. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J Thromb Haemost 2008 6 1 197-200
9. Prechel M M., McDonald M K., Jeske W P., Messmore H L., Walenga J M. Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005 3 10 2168-2175 (Pubitemid 41727193)
10. Warkentin T E., Bernstein R A. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003 348 11 1067-1069 (Pubitemid 36302259)
11. Greinacher A, Warkentin T E. The direct thrombin inhibitor hirudin. Thromb Haemost 2008 99 5 819-829 (Pubitemid 351705298)
12. Warkentin T E., Levine M N., Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995 332 20 1330-1335
13. Warkentin T E., Roberts R S., Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003 163 20 2518-2524 (Pubitemid 37385796)
14. Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T E. Greinacher A eds. Heparin-Induced Thrombocytopenia. 4th ed. New York Informa Healthcare USA 2007 21-66
15. Warkentin T E., Elavathil L J., Hayward C PM, Johnston M A., Russett J I., Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997 127 9 804-812 (Pubitemid 27465548)
16. Srinivasan A F., Rice L, Bartholomew J R. et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004 164 1 66-70 (Pubitemid 38067390)
17. Warkentin T E. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 2006 4 4 894-896
18. Warkentin T E., Sheppard J A., Sigouin C S., Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006 108 9 2937-2941
19. Warkentin T E., Cook R J., Marder V J. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005 106 12 3791-3796 (Pubitemid 41739014)
20. Salem M, Elrefai S, Shrit M A., Warkentin T E. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 2010 104 5 1071-1072
21. Greinacher A, Gopinadhan M, Günther J U. et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006 26 10 2386-2393 (Pubitemid 44465738)
22. Greinacher A, Alban S, Omer-Adam M A., Weitschies W, Warkentin T E. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008 122 2 211-220
23. Pouplard C, May M A., Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005 128 6 837-841 (Pubitemid 40444878)
24. Lubenow N, Hinz P, Thomaschewski S et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010 115 9 1797-1803
25. Warkentin T E., Sheppard J A., Moore J C., Cook R J., Kelton J G. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009 113 20 4963-4969
26. Warkentin T E., Greinacher A, Koster A, Lincoff A M., American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 6, Suppl 340S-380S Erratum in: Chest. 2011;139(5):1261. Dosage error in article text. (Pubitemid 351892970)
27. ten Berg M J., van den Bemt PMLA, Huisman A, Schobben AFAM, Egberts T CG, van Solinge W W. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. Ann Pharmacother 2009 43 9 1405-1412
28. Riggio J M., Cooper M K., Leiby B E., Walenga J M., Merli G J., Gottlieb J E. Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia. J Thromb Thrombolysis 2009 28 2 124-131
29. Rogers B A., Cowie A S. The monitoring of heparin induced thrombocytopenia following surgery: an audit and international survey. J Perioper Pract 2010 20 2 66-69
30. Chong B H., Magnani H N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin T E. Greinacher A eds. Heparin-Induced Thrombocytopenia. 4th ed. New York Informa Healthcare USA 2007 319-343
31. Lubenow N, Warkentin T E., Greinacher A et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006 117 5 507-515 (Pubitemid 43326135)
32. Warkentin T E. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 2010 3 5 567-581
33. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin T E. Greinacher A eds. Heparin-Induced Thrombocytopenia. 4th ed. New York Informa Healthcare USA 2007 345-378
34. Lewis B E., Hursting M J. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin T E. Greinacher A eds. Heparin-Induced Thrombocytopenia. 4th ed. New York Informa Healthcare USA 2007 379-408
35. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001 85 6 950-957 (Pubitemid 32573742)
36. Warkentin T E., Sheppard J I., Moore J C., Sigouin C S., Kelton J G. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008 6 8 1304-1312 (Pubitemid 352016309)
37. Warkentin T E., Kelton J G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001 344 17 1286-1292 (Pubitemid 32372963)
38. Lee A Y., Levine M N., Baker R I. et al, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003 349 2 146-153 (Pubitemid 36818784)
39. Amiral J, Vissac A M. Role of heparin-dependent antigens in immune heparin-induced thrombocytopenia. In: Warkentin T E. Greinacher A eds. Heparin-Induced Thrombocytopenia. 4th ed. New York Informa Healthcare USA 2007 131-147
40. Girolami B, Prandoni P, Stefani P M. et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003 101 8 2955-2959 (Pubitemid 36857979)
41. Prandoni P, Siragusa S, Girolami B, Fabris F, BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005 106 9 3049-3054 (Pubitemid 41565898)
42. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res 2007 120 Suppl 2 S137-S140 (Pubitemid 350101783)
43. Opatrny L, Warner M N. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004 76 3 240-244 (Pubitemid 38828843)
44. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2008 36 3-4 122-130
45. Gruel Y, Pouplard C, Nguyen P et al, French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003 121 5 786-792 (Pubitemid 36718197)
46. Warkentin T E. HIT paradigms and paradoxes. J Thromb Haemost 2011 9 Supp. 1 105-117